Plexxikon Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (48)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Plexxikon - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Plexxikon. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline and majority of them are in phase-I. There are 3 cancer drugs by Plexxikon which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Plexxikon - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Plexxikon - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Plexxikon. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline and majority of them are in phase-I. There are 3 cancer drugs by Plexxikon which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Plexxikon - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Plexxikon

  1.1 Business Overview

  1.2 Plexxikon Cancer Pipeline Overview

 

2. Plexxikon Cancer Drugs in Preclinical Phase

  2.1 Kinase Inhibitors - Plexxikon

 

3. Plexxikon Cancer Drugs in Phase-I

  3.1 PLX 51107

  3.2 PLX 7486

  3.3 PLX 9486

  3.4 PLX 73086

 

4. Plexxikon Cancer Drugs in Phase-I/II

  4.1 PLX 8394

 

5. Plexxikon Cancer Drugs in Phase-II

  5.1 Pexidartinib

  5.2 Interleukin-12 Gene Therapy - OncoSec Medical

 

6. Plexxikon Cancer Drugs in Phase-III

  6.1 Durvalumab

 

7. Marketed Cancer Drugs by Plexxikon

  7.1 Pembrolizumab (Keytruda)

  7.2 Vemurafenib

  7.3 Vemurafenib Companion Diagnostic (cobas 4800 BRAF V600 Mutation Test)

 

8. No Development Reported in Cancer Drugs in Clinical Pipeline

  8.1 Anticancer Therapeutics - Plexxikon/Genentech

 

9. Discontinued in Cancer Drugs in Clinical Pipeline

  9.1 RG 7256


Figure 1-1: Plexxikon Cancer Pipeline by Phase (%)

Figure 1-2: Plexxikon Cancer Pipeline by Phase (Number)

Figure 1-3: Plexxikon Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Plexxikon Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)